IRIS Accounts Production v24.3.2.46 10837397 director 1.7.23 30.6.24 30.6.24 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh108373972023-06-30108373972024-06-30108373972023-07-012024-06-30108373972022-06-30108373972022-07-012023-06-30108373972023-06-3010837397ns15:EnglandWales2023-07-012024-06-3010837397ns14:PoundSterling2023-07-012024-06-3010837397ns10:Director12023-07-012024-06-3010837397ns10:PrivateLimitedCompanyLtd2023-07-012024-06-3010837397ns10:SmallEntities2023-07-012024-06-3010837397ns10:AuditExempt-NoAccountantsReport2023-07-012024-06-3010837397ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-3010837397ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-3010837397ns10:FullAccounts2023-07-012024-06-3010837397ns10:CompanySecretary12023-07-012024-06-3010837397ns10:RegisteredOffice2023-07-012024-06-3010837397ns5:CurrentFinancialInstruments2024-06-3010837397ns5:CurrentFinancialInstruments2023-06-3010837397ns5:Non-currentFinancialInstruments2024-06-3010837397ns5:Non-currentFinancialInstruments2023-06-3010837397ns5:ShareCapital2024-06-3010837397ns5:ShareCapital2023-06-3010837397ns5:RetainedEarningsAccumulatedLosses2024-06-3010837397ns5:RetainedEarningsAccumulatedLosses2023-06-3010837397ns5:MotorVehicles2023-07-012024-06-3010837397ns5:ComputerEquipment2023-07-012024-06-3010837397ns5:MotorVehicles2023-06-3010837397ns5:ComputerEquipment2023-06-3010837397ns5:MotorVehicles2024-06-3010837397ns5:ComputerEquipment2024-06-3010837397ns5:MotorVehicles2023-06-3010837397ns5:ComputerEquipment2023-06-3010837397ns5:WithinOneYearns5:CurrentFinancialInstruments2024-06-3010837397ns5:WithinOneYearns5:CurrentFinancialInstruments2023-06-3010837397ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2024-06-3010837397ns5:Non-currentFinancialInstrumentsns5:MoreThanFiveYears2023-06-30108373971ns10:Director12023-06-30108373971ns10:Director12022-06-30108373971ns10:Director12023-07-012024-06-30108373971ns10:Director12022-07-012023-06-30108373971ns10:Director12024-06-30108373971ns10:Director12023-06-30
REGISTERED NUMBER: 10837397 (England and Wales)















Unaudited Financial Statements for the Year Ended 30 June 2024

for

Oral Surgery And Implantology Limited

Oral Surgery And Implantology Limited (Registered number: 10837397)






Contents of the Financial Statements
for the Year Ended 30 June 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Oral Surgery And Implantology Limited

Company Information
for the Year Ended 30 June 2024







DIRECTOR: Mr Arash Zaker Shahrak



SECRETARY: Mrs Farnaz Akbarian Tefaghi



REGISTERED OFFICE: Unit 3 Cedar Court
1 Royal Oak Yard
London
SE1 3GA



REGISTERED NUMBER: 10837397 (England and Wales)



ACCOUNTANTS: ElanTax.com
Unit 3 Cedar Court
1 Royal Oak Yard
London
SE1 3GA



BANKERS: Starling Bank Limited
5Th Floor
London Fruit And Wool Exchange
1 Duval Square
London
EC2M 2PP

Oral Surgery And Implantology Limited (Registered number: 10837397)

Balance Sheet
30 June 2024

30.6.24 30.6.23
Notes £    £    £    £   
FIXED ASSETS
Tangible assets 4 19,972 25,402

CURRENT ASSETS
Debtors 5 145,217 83,072
Cash at bank and in hand 5,026 5,303
150,243 88,375
CREDITORS
Amounts falling due within one year 6 147,940 80,532
NET CURRENT ASSETS 2,303 7,843
TOTAL ASSETS LESS CURRENT
LIABILITIES

22,275

33,245

CREDITORS
Amounts falling due after more than one
year

7

19,347

32,729
NET ASSETS 2,928 516

CAPITAL AND RESERVES
Called up share capital 200 200
Retained earnings 2,728 316
SHAREHOLDERS' FUNDS 2,928 516

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30 June 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30 June 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Oral Surgery And Implantology Limited (Registered number: 10837397)

Balance Sheet - continued
30 June 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 27 March 2025 and were signed by:





Mr Arash Zaker Shahrak - Director


Oral Surgery And Implantology Limited (Registered number: 10837397)

Notes to the Financial Statements
for the Year Ended 30 June 2024

1. STATUTORY INFORMATION

Oral Surgery And Implantology Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Fees receivable is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Motor vehicles - 25% on reducing balance
Office equipment - 33% on cost

Taxation
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 1 (2023 - 1 ) .

4. TANGIBLE FIXED ASSETS
Motor Office
vehicles equipment Totals
£    £    £   
COST
At 1 July 2023 43,828 9,056 52,884
Additions - 1,999 1,999
At 30 June 2024 43,828 11,055 54,883
DEPRECIATION
At 1 July 2023 19,175 8,307 27,482
Charge for year 6,163 1,266 7,429
At 30 June 2024 25,338 9,573 34,911
NET BOOK VALUE
At 30 June 2024 18,490 1,482 19,972
At 30 June 2023 24,653 749 25,402

Oral Surgery And Implantology Limited (Registered number: 10837397)

Notes to the Financial Statements - continued
for the Year Ended 30 June 2024

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.24 30.6.23
£    £   
Trade debtors 25,809 10,000
Other debtors 600 450
S455 tax receivable 22,658 11,004
Directors' current accounts 96,150 61,618
145,217 83,072

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
30.6.24 30.6.23
£    £   
Tax 144,899 77,700
Social security and other taxes 379 -
Accrued expenses 2,662 2,832
147,940 80,532

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE YEAR
30.6.24 30.6.23
£    £   
Bounce back loan 4,504 6,854
Hire purchase contracts 14,843 25,875
19,347 32,729

8. DIRECTOR'S ADVANCES, CREDITS AND GUARANTEES

The following advances and credits to a director subsisted during the years ended 30 June 2024 and 30 June 2023:

30.6.24 30.6.23
£    £   
Mr Arash Zaker Shahrak
Balance outstanding at start of year 61,618 29,016
Amounts advanced 34,532 32,602
Amounts repaid - -
Amounts written off - -
Amounts waived - -
Balance outstanding at end of year 96,150 61,618

9. RELATED PARTY DISCLOSURES

The company was under the control of Mr A Shahrak, a director and members of his close family throughout the current period. Mr A Shahrak is personally interested in 50% of the company's share capital. In addition, his spouse controls a further 50% of the company's issued share capital.